Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)
The CHRONICLE Study: A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals With Severe Asthma in the United States
1 other identifier
observational
18
2 countries
175
Brief Summary
The CHRONICLE Study is a multi-center, non-interventional, prospective cohort study of adults with severe asthma who do not achieve control with high-dose inhaled corticosteroid (ICS) therapy with additional controllers and/or require systemic corticosteroid or monoclonal antibody therapy. Data will be collected from the healthcare provider in a uniform manner for every patient enrolled using an electronic case report form (eCRF). Data will be collected monthly from patients via web-based surveys. Patients will be followed until study discontinuation or the patient withdraws from the study or death, whichever occurs first. The expectation is that patients will be followed for a period of at least 3 years.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Feb 2018
Longer than P75 for all trials
175 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 20, 2017
CompletedFirst Posted
Study publicly available on registry
December 14, 2017
CompletedStudy Start
First participant enrolled
February 27, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 14, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
February 14, 2025
CompletedSeptember 24, 2025
September 1, 2025
7 years
November 20, 2017
September 22, 2025
Conditions
Keywords
Outcome Measures
Primary Outcomes (20)
Healthcare utilization- hospitalizations, clinic Visits, and asthma exacerbations
Longitudinal changes of Healthcare utilization will be measured using directly collected information from medical, hospital, and pharmacy records to provide a supplementary comprehensive assessment of each patient's healthcare utilization during the study period.
At baseline, every 6 months, through study completion, assessed up to 7 years.
Asthma treatment
Asthma medications with dose and start/stop dates including all FDA-approved and standard of care treatments for asthma will be assessed. Longitudinal changes in asthma treatment will also be assessed.
At baseline, every 6 months, through study completion, assessed up to 7 years.
Treatment adherence
Extraction of electronic medical, hospital, and pharmacy records will take place at study close and potentially at interim time points to provide a supplementary assessment of each patient's healthcare resource utilization. Longitudinal changes in patient reported treatment adherence will also be assessed.
At baseline, every 1 month, through study completion, assessed up to 7 years.
Asthma control test (ACT)
Patient-reported asthma symptoms and control will be collected via the ACT questionnaire; a 5 item, self-administered survey that is designed to help the patient describe their asthma and how it affects their daily activities. ACT questionnaire is a 5-point scale (for symptoms and activities: 1=all the time to 5= not at all; for asthma control rating: 1=not controlled at all to 5=completely controlled). In 2022, the ACT survey will be removed, and only the AIRQ will be solicited monthly.
Change from baseline, every 1 month, through study completion, assessed up to 4 years.
Patient-reported asthma exacerbations
Asthma exacerbations, the primary analytical definition will be worsening of asthma that leads to any of the following: Use of systemic corticosteroids (or a temporary increase in a stable corticosteroid background dose) for at least 3 days; a single depo-injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids. An emergency department or urgent care visit (defined as evaluation and treatment for \<24 hours in an emergency department or urgent care center) due to asthma that required systemic corticosteroids. An inpatient hospitalization (defined as admission to an inpatient facility and/or evaluation and treatment in a healthcare facility for ≥24 hours) due to asthma. In 2022, the asthma exacerbations survey will be removed, and only the AIRQ will be solicited monthly.
Change from baseline, every 1 month, through study completion, assessed up to 4 years.
Asthma Impairment and Risk Questionnaire (AIRQ)
AIRQ is a 10-item, equally weighted, yes/no composite asthma control questionnaire that includes 7 impairment and 3 risk items. AIRQ scores range from 0 to 10, with lower scores representing better controlled asthma.
At baseline, every 1 month, through study completion, assessed up to 4 years
Work Productivity and Activity Impairment Asthma questionnaire (WPAI-Asthma)
Patient-reported productivity impairment assessment including work productivity, activity impairment, and disability will be collected via the WPAI-Asthma. Information will only be collected from procedures that are part of the patient's routine clinical care. WPAI Asthma questionnaire is calculated from 0 to 10 score (0 indicates-Asthma had no effect on my work/ daily activities and 10 indicates Asthma completely prevented me from working score/ doing my daily activities).
At baseline, every 3 months, through study completion, assessed up to 7 years.
St. George's Respiratory Questionnaire (SGRQ)
Patient-reported assessment of asthma quality of life will be collected via the SGRQ. SGRQ, a disease specific health-related quality of life measure developed for both asthma and chronic obstructive pulmonary disease (COPD) patients. The SGRQ has 50 items and scores are calculated for 3 domains (symptoms, activity, and impact \[psychosocial\]) as well as total score. Symptoms - this component is concerned with the effect of respiratory symptoms, their frequency and severity. Impacts (psychosocial) - covers a range of aspects concerned with social functioning and psychological disturbances resulting from respiratory disease Activity - concerned with activities that cause or are limited by breathlessness. Total score summarizes the impact of the disease on overall health status. The score is expressed as a percentage of overall impairment, where 100 represents worst possible health status and 0 indicates best possible health status.
At baseline, every 6 months, through study completion, assessed up to 7 years.
Global evaluation of treatment effectiveness (GETE)
Patient evaluation of asthma treatment effectiveness will be measured using GETE; a simple measure of perceived treatment effectiveness. The patient will grade the overall treatment effectiveness using the following criteria: excellent (complete control of asthma); good (marked improvement of asthma); moderate (discernible, but limited improvement in asthma); poor (no appreciable change in asthma); or worsening (of asthma).
At baseline, every 6 months, through study completion, assessed maximum up to 7 years.
Number of Participants With Adverse Events associated with corticosteroid therapy
Frequency of relevant medical events such as weight gain (change in BMI), hypertension, dyslipidemia, pneumonia, bone densitometry results, osteoporosis / osteopenia, hip and spinal fractures, avascular necrosis, cataract, glaucoma, diabetes mellitus, cardiovascular disease, Cushing's syndrome, adrenal insufficiency, peptic ulcer disease, myopathy, pseudotumor cerebri, mood disturbance, and insomnia or sleep disturbance.
At baseline, every 6 months, through study completion, assessed up to 7 years.
Relevant respiratory medical events
Frequency of relevant respiratory medical events such as pneumonia, pleural effusion, chronic bronchitis, allergic rhinitis.
At baseline, every 6 months, through study completion,assessed up to 7 years.
Respiratory comorbidities
Prevalence of respiratory comorbidities such as chronic obstructive pulmonary disease (COPD), bronchiectasis, alpha-1 anti-trypsin deficiency, Churg- Strauss syndrome (eosinophilic granulomatosis with polyangiitis \[EGPA\]), airway stenosis, cystic fibrosis, allergic bronchopulmonary aspergillosis,chronic eosinophilic pneumonia, bronchiolitis obliterans, immunodeficiency, primary ciliary dyskinesia, atelectasis, arterial hypertension, pulmonary hypertension, neuromuscular disease, allergic rhinitis, chronic rhinosinusitis, and pulmonary embolism.
At baseline, every 6 months, through study completion, assessed up to 7 years.
Non-respiratory comorbidities
Prevalence of non-respiratory comorbidities such as diabetes, thyroid disease, cardiac disease, etc.
At baseline, every 6 months, through study completion, assessed up to 7 years.
Events of special interest
Frequency of special interest events including new onset malignancy, severe infection, anaphylaxis, or mortality.
At baseline, every 6 months, through study completion, assessed up to 7 years.
Complete blood count with differential including blood eosinophil count.
To assess complete blood count with differential including blood eosinophil count as a variable for asthma evaluation.
Change from baseline, every 6 months, through study completion, assessed up to 7 years.
Total immunoglobulin E (IgE)
To assess total IgE as a variable for asthma evaluation.
Change from baseline, every 6 months, through study completion, assessed up to 7 years.
Radiographic changes in asthma evaluation.
Radiographic changes in asthma evaluation included chest X-rays (dates, views, description of major chest findings), Chest computed tomography scan (dates, high resolution (yes/no), intravenous contrast (yes/no), description of major findings). Radiographic asthma evaluation conducted as part of routine care.
Change from baseline, every 6 months, through study completion, assessed up to 7 years.
Forced Vital Capacity (FVC)
FEV1 (liters and % predicted) will be assessed as a variable for asthma evaluation.
Change from baseline, every 6 months, through study completion, assessed up to 7 years.
Forced Expiratory Volume in 1 second (FEV1)
FEV1 (liters and % predicted) will be assessed as a variable for asthma evaluation.
Change from baseline, every 6 months, through study completion, assessed up to 7 years.
Fractional exhaled nitric oxide (FENO)
To assess FENO as a variable for asthma evaluation.
Change from baseline, every 6 months, through study completion, assessed up to 7 years.
Study Arms (1)
Cohort of US adults with severe asthma
To describe patient characteristics, treatment patterns, and health outcomes among a large, geographically diverse cohort of US adults with severe asthma who are not controlled on high-dose ICS with additional controllers and/or require chronic systemic corticosteroid or monoclonal antibody therapy.
Eligibility Criteria
It is estimated that at least 1500 patients in the US with a confirmed diagnosis of severe asthma will be enrolled by a diverse set of asthma specialists (eg, allergists and pulmonologists who treat asthma) from academic and community-based centers.
You may qualify if:
- \. Individuals with a diagnosis of severe asthma for at least 12 months prior to enrollment and confirmed by the Investigator not to be due to alternative diagnoses.
- \. Currently receiving care from specialist physicians (eg, pulmonologists and or allergists) at the Investigator's or sub-investigator's site.
- \. 18 years of age and older. 4. Meeting at least one of the following three criteria (a, b, or c):
- a. Uncontrolled asthma while receiving high-dose ICS with additional controllers.
- i. Uncontrolled is defined by meeting at least one of the following (as outlined by ATS/ERS \[American Thoracic Society/European Respiratory Society\] guidelines):
- Poor symptom control: Asthma Control Questionnaire consistently ≥1.5, ACT \<20 (or "not well controlled" by NAEPP \[National Asthma Education and Prevention Program\]/Global Initiative for Asthma guidelines).
- Frequent severe exacerbations: two or more bursts of systemic corticosteroids (≥3 days each) in the previous 12 months.
- Serious exacerbations: at least one hospitalization, intensive care unit stay or mechanical ventilation in the previous 12 months.
- Airflow limitation: after appropriate bronchodilator withhold FEV1 \<80% predicted (in the face of reduced FEV1/FVC defined as less than the lower limit of normal).
- ii. For the purposes of this study, high-dose ICS will be defined as
- \. ICS at a cumulative dose of \>500 μg fluticasone propionate equivalents daily as defined in Appendix A, or 2. Highest labeled dose of a combination of ICS/LABA. b. Current use of a Food and Drug Administration (FDA)-approved monoclonal antibody agent for treatment of severe asthma (use is not primarily for an alternative condition).
- c. Use of systemic corticosteroids or other systemic immunosuppressants (any dose level) for approximately 50% or more of the prior 12 months for treatment of severe asthma (use is not primarily for an alternative condition).
You may not qualify if:
- Not willing and able to sign written informed consent. Consent can be obtained from having a responsible, legally authorized representative acting on patient's behalf.
- Not fluent in English or Spanish.
- Inability to complete study follow-up or web-based PROs. If the patient does not have email or web access, minimal assistance from others to access the web-based PRO is permitted (ie receiving the email and/or assisting patient in navigating to the web page); PROs must be completed by the patient.
- Received an investigational therapy for asthma, allergy, atopic disease, or eosinophilic disease as part of a clinical trial during the 6 months prior to enrollment.
- Once enrolled in the CHRONICLE Study, patients can enroll in trials of investigational therapies (as well as other non-interventional studies) as long as they continue to complete study follow-up. If a patient enrolls in a trial of an investigational therapy, the identity (National Clinical Trial \[NCT\] number) of the study and dates of the first and last investigational therapy administrations will be collected. If a patient receives blinded therapy in a trial, the Investigator will request the identity of that therapy at trial conclusion so that treatment information collected for the current study may be updated accordingly.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
- Parexelcollaborator
- MedImmune LLCcollaborator
Study Sites (175)
Research Site
Birmingham, Alabama, 35209, United States
Research Site
Birmingham, Alabama, 35294, United States
Research Site
Hoover, Alabama, 35244, United States
Research Site
Gilbert, Arizona, 85234, United States
Research Site
Peoria, Arizona, 85381, United States
Research Site
Little Rock, Arkansas, 72205, United States
Research Site
Bakersfield, California, 93301, United States
Research Site
Loma Linda, California, 92354, United States
Research Site
Los Angeles, California, 90025, United States
Research Site
Mission Viejo, California, 92691, United States
Research Site
Modesto, California, 95355-4201, United States
Research Site
Redondo Beach, California, 90277, United States
Research Site
Riverside, California, 92506, United States
Research Site
Roseville, California, 95661, United States
Research Site
Sacramento, California, 95819, United States
Research Site
San Diego, California, 92103, United States
Research Site
San Diego, California, 92123, United States
Research Site
San Diego, California, 92130-3318, United States
Research Site
Santa Monica, California, 90404, United States
Research Site
Studio City, California, 91607, United States
Research Site
Ventura, California, 93003, United States
Research Site
Westminster, California, 92683, United States
Research Site
Aurora, Colorado, 80045, United States
Research Site
Danbury, Connecticut, 06810, United States
Research Site
Farmington, Connecticut, 06030, United States
Research Site
New Haven, Connecticut, 06510, United States
Research Site
Waterbury, Connecticut, 06708, United States
Research Site
Newark, Delaware, 19713, United States
Research Site
Brandon, Florida, 33511, United States
Research Site
Clearwater, Florida, 33765, United States
Research Site
Coral Gables, Florida, 33134, United States
Research Site
Gainesville, Florida, 32608, United States
Research Site
Jacksonville, Florida, 32204, United States
Research Site
Kissimmee, Florida, 34759, United States
Research Site
Lake Mary, Florida, 32746, United States
Research Site
Miami, Florida, 33032, United States
Research Site
Miami, Florida, 33175, United States
Research Site
Miami, Florida, 33176, United States
Research Site
Miami Beach, Florida, 33140, United States
Research Site
Pensacola, Florida, 32504, United States
Research Site
Plantation, Florida, 33317, United States
Research Site
St. Petersburg, Florida, 33704, United States
Research Site
Tallahassee, Florida, 32308, United States
Research Site
Tampa, Florida, 32789, United States
Research Site
Tampa, Florida, 33613, United States
Research Site
Albany, Georgia, 31707, United States
Research Site
Decatur, Georgia, 30033, United States
Research Site
Gainesville, Georgia, 30501, United States
Research Site
Villa Rica, Georgia, 30180, United States
Research Site
Boise, Idaho, 83706, United States
Research Site
Chicago, Illinois, 60611, United States
Research Site
Chicago, Illinois, 60612, United States
Research Site
Glen Ellyn, Illinois, 60137, United States
Research Site
Fort Wayne, Indiana, 46804, United States
Research Site
Iowa City, Iowa, 52242, United States
Research Site
West Des Moines, Iowa, 50266, United States
Research Site
Overland Park, Kansas, 66210, United States
Research Site
Georgetown, Kentucky, 40324, United States
Research Site
Lexington, Kentucky, 40503, United States
Research Site
Lexington, Kentucky, 40509, United States
Research Site
Louisville, Kentucky, 40215, United States
Research Site
New Orleans, Louisiana, 70112, United States
Research Site
New Orleans, Louisiana, 70127, United States
Research Site
Shreveport, Louisiana, 71106, United States
Research Site
Bangor, Maine, 04401, United States
Research Site
Rockville, Maryland, 20850, United States
Research Site
Rockville, Maryland, 20852, United States
Research Site
Silver Spring, Maryland, 20902, United States
Research Site
Burlington, Massachusetts, 01805, United States
Research Site
North Dartmouth, Massachusetts, 02747, United States
Research Site
Ann Arbor, Michigan, 48106, United States
Research Site
Ann Arbor, Michigan, 48109, United States
Research Site
Clinton Township, Michigan, 48038, United States
Research Site
Detroit, Michigan, 48202, United States
Research Site
Hamtramck, Michigan, 48211, United States
Research Site
Wyoming, Michigan, 49519, United States
Research Site
Maplewood, Minnesota, 55109, United States
Research Site
Minneapolis, Minnesota, 55455, United States
Research Site
Plymouth, Minnesota, 55402, United States
Research Site
Rochester, Minnesota, 55905, United States
Research Site
St Louis, Missouri, 63110, United States
Research Site
Lincoln, Nebraska, 68505, United States
Research Site
Omaha, Nebraska, 68105, United States
Research Site
Omaha, Nebraska, 68114, United States
Research Site
Omaha, Nebraska, 68124, United States
Research Site
Las Vegas, Nevada, 89106, United States
Research Site
Brick, New Jersey, 08724, United States
Research Site
Marlton, New Jersey, 08053, United States
Research Site
New Brunswick, New Jersey, 08901, United States
Research Site
North Bergen, New Jersey, 07047, United States
Research Site
Northfield, New Jersey, 08225, United States
Research Site
Toms River, New Jersey, 08755, United States
Research Site
Verona, New Jersey, 07044, United States
Research Site
Albuquerque, New Mexico, 87109, United States
Research Site
Bayside, New York, 11361, United States
Research Site
Brooklyn, New York, 11230, United States
Research Site
Brooklyn, New York, 11236, United States
Research Site
Corning, New York, 14830, United States
Research Site
Great Neck, New York, 11023, United States
Research Site
Jamaica, New York, 11418, United States
Research Site
Mineola, New York, 11501, United States
Research Site
New Hyde Park, New York, 11042, United States
Research Site
New Paltz, New York, 12561, United States
Research Site
New York, New York, 10022, United States
Research Site
Rochester, New York, 14621, United States
Research Site
Rochester, New York, 14642, United States
Research Site
Rockville Centre, New York, 11570, United States
Research Site
Staten Island, New York, 10305, United States
Research Site
The Bronx, New York, 10458, United States
Research Site
The Bronx, New York, 10459, United States
Research Site
The Bronx, New York, 10461, United States
Research Site
The Bronx, New York, 10465, United States
Research Site
Valhalla, New York, 10595, United States
Research Site
Asheville, North Carolina, 28801, United States
Research Site
Chapel Hill, North Carolina, 27599, United States
Research Site
Charlotte, North Carolina, 28204, United States
Research Site
Charlotte, North Carolina, 28277, United States
Research Site
Durham, North Carolina, 27701, United States
Research Site
Fayetteville, North Carolina, 28304, United States
Research Site
Greenville, North Carolina, 27834, United States
Research Site
Winston-Salem, North Carolina, 27157, United States
Research Site
Fargo, North Dakota, 58104, United States
Research Site
Toledo, Ohio, 43617, United States
Research Site
Oklahoma City, Oklahoma, 73120, United States
Research Site
Oklahoma City, Oklahoma, 73131, United States
Research Site
Corvallis, Oregon, 97330, United States
Research Site
Portland, Oregon, 97220, United States
Research Site
Portland, Oregon, 97225, United States
Research Site
Altoona, Pennsylvania, 16601, United States
Research Site
Blue Bell, Pennsylvania, 19422, United States
Research Site
DuBois, Pennsylvania, 15801, United States
Research Site
Harrisburg, Pennsylvania, 17109, United States
Research Site
Philadelphia, Pennsylvania, 19107, United States
Research Site
Pittsburgh, Pennsylvania, 15241, United States
Research Site
Sayre, Pennsylvania, 18840, United States
Research Site
Yardley, Pennsylvania, 19067, United States
Research Site
Lincoln, Rhode Island, 02865, United States
Research Site
Clinton, South Carolina, 29325, United States
Research Site
Greenville, South Carolina, 29607, United States
Research Site
Mt. Pleasant, South Carolina, 29464, United States
Research Site
North Charleston, South Carolina, 29420, United States
Research Site
Rock Hill, South Carolina, 29732, United States
Research Site
Franklin, Tennessee, 37064, United States
Research Site
Hendersonville, Tennessee, 37075, United States
Research Site
Aransas Pass, Texas, 78336, United States
Research Site
Beaumont, Texas, 77702, United States
Research Site
Dallas, Texas, 75246, United States
Research Site
Denison, Texas, 75020, United States
Research Site
Duncanville, Texas, 75116, United States
Research Site
Fort Worth, Texas, 76107, United States
Research Site
Houston, Texas, 77030, United States
Research Site
Houston, Texas, 77043, United States
Research Site
Houston, Texas, 77079, United States
Research Site
Katy, Texas, 77450, United States
Research Site
Kingwood, Texas, 77339, United States
Research Site
Live Oak, Texas, 78233, United States
Research Site
McKinney, Texas, 75069, United States
Research Site
San Antonio, Texas, 78251, United States
Research Site
Sugar Land, Texas, 77478, United States
Research Site
Murray, Utah, 84107, United States
Research Site
Salt Lake City, Utah, 84132, United States
Research Site
Lynchburg, Virginia, 24501, United States
Research Site
Newport News, Virginia, 23606, United States
Research Site
Norfolk, Virginia, 23507, United States
Research Site
Richmond, Virginia, 23229, United States
Research Site
Richmond, Virginia, 23235, United States
Research Site
Richmond, Virginia, 23298, United States
Research Site
Tacoma, Washington, 98405, United States
Research Site
Vancouver, Washington, 98664, United States
Research Site
Charleston, West Virginia, 25304, United States
Research Site
Greenfield, Wisconsin, 53228, United States
Research Site
Madison, Wisconsin, 53792-9988, United States
Research Site
Onalaska, Wisconsin, 54650, United States
Research Site
Wausau, Wisconsin, 54401, United States
Research Site
Guaynabo, 00968, Puerto Rico
Related Publications (10)
Panettieri RA Jr, Mohan A, Lugogo NL, Ledford DK, Carstens DD, Ambrose CS. Outcomes after biologic initiation among patients with severe asthma and normal lung function in the CHRONICLE study. Respir Res. 2026 Jan 7;27(1):5. doi: 10.1186/s12931-025-03439-8.
PMID: 41501790DERIVEDLedford DK, Carr WW, Moore WC, Lugogo NL, Mohan A, Chipps B, Mackie AR, Lindsley AW, Spahn J, Ambrose CS. Reduced Effectiveness of Anti-IgE Treatment Among Adults with Severe Asthma with Older Age of Asthma Onset: Results from the CHRONICLE Study. J Asthma Allergy. 2024 Oct 9;17:977-982. doi: 10.2147/JAA.S476774. eCollection 2024.
PMID: 39398317DERIVEDLedford DK, Soong W, Carr W, Trevor J, Tan L, Carstens D, Ambrose CS. Real-world severe asthma biologic administration and adherence differs by biologic: CHRONICLE study results. Ann Allergy Asthma Immunol. 2023 Nov;131(5):598-605.e3. doi: 10.1016/j.anai.2023.07.017. Epub 2023 Jul 26.
PMID: 37506846DERIVEDChipps BE, Soong W, Panettieri RA Jr, Carr W, Gandhi H, Zhou W, Cook B, Llanos JP, Ambrose CS. Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2023 Jun;130(6):784-790.e5. doi: 10.1016/j.anai.2023.03.001. Epub 2023 Mar 10.
PMID: 36906262DERIVEDPanettieri RA Jr, Ledford DK, Chipps BE, Soong W, Lugogo N, Carr W, Mohan A, Carstens D, Genofre E, Trudo F, Ambrose CS. Biologic use and outcomes among adults with severe asthma treated by US subspecialists. Ann Allergy Asthma Immunol. 2022 Oct;129(4):467-474.e3. doi: 10.1016/j.anai.2022.06.012. Epub 2022 Jun 19.
PMID: 35728746DERIVEDPanettieri RA Jr, Chipps BE, Moore WC, Soong W, Carr WW, Kreindler JL, O'Quinn S, Trudo F, Ambrose CS. Differing perceptions of asthma control and treatment effectiveness by patients with severe asthma and treating subspecialists in the United States. J Asthma. 2022 Sep;59(9):1859-1868. doi: 10.1080/02770903.2021.1963766. Epub 2021 Nov 5.
PMID: 34374622DERIVEDTrevor J, Lugogo N, Carr W, Moore WC, Soong W, Panettieri RA Jr,, Desai P, Trudo F, Ambrose CS. Severe asthma exacerbations in the United States:: Incidence, characteristics, predictors, and effects of biologic treatments. Ann Allergy Asthma Immunol. 2021 Nov;127(5):579-587.e1. doi: 10.1016/j.anai.2021.07.010. Epub 2021 Jul 15.
PMID: 34273485DERIVEDSoong W, Chipps BE, O'Quinn S, Trevor J, Carr WW, Belton L, Trudo F, Ambrose CS. Health-Related Quality of Life and Productivity Among US Patients with Severe Asthma. J Asthma Allergy. 2021 Jun 25;14:713-725. doi: 10.2147/JAA.S305513. eCollection 2021.
PMID: 34211280DERIVEDAmbrose CS, Chipps BE, Moore WC, Soong W, Trevor J, Ledford DK, Carr WW, Lugogo N, Trudo F, Tran TN, Panettieri RA Jr. The CHRONICLE Study of US Adults with Subspecialist-Treated Severe Asthma: Objectives, Design, and Initial Results. Pragmat Obs Res. 2020 Jul 16;11:77-90. doi: 10.2147/POR.S251120. eCollection 2020.
PMID: 32765156DERIVEDMoore WC, Panettieri RA Jr, Trevor J, Ledford DK, Lugogo N, Soong W, Chipps BE, Carr W, Belton L, Gandhi H, Trudo F, Ambrose CS. Biologic and maintenance systemic corticosteroid therapy among US subspecialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2020 Sep;125(3):294-303.e1. doi: 10.1016/j.anai.2020.04.004. Epub 2020 Apr 15.
PMID: 32304877DERIVED
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 5 Years
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 20, 2017
First Posted
December 14, 2017
Study Start
February 27, 2018
Primary Completion
February 14, 2025
Study Completion
February 14, 2025
Last Updated
September 24, 2025
Record last verified: 2025-09
Data Sharing
- IPD Sharing
- Will not share